Vascular Biology and Metabolism (VAM)

< Back

Overview

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

Publications

248
total
1470
impact factor
5.93
average impact factor

Group Leader: Ignacio Ferreira González

group-team team group-zoom zoom group-download download

Research Areas

During 2019 a large multidisciplinary international cooperative project on the pathophysiology of cardiomyopathy in type 2 diabetes mellitus (CARDIA-TEAM), has been funded by European Commission. This innovative translational project involves 6 CIBER-CV groups and our group, along with Diabetes & Metabolism group lead one package. In addition, the independent multicenter clinical trial on ischemia-reperfusion in myocardial infarction (COMBAT-MI) leaded by our group has been completed and results have been presented during the prestigious late-breaking clinical trials of the European Society of Cardiology Congress. Important articles have been published on ischemic heart disease (in relation with cardiac ageing, risk factors, management of acute events), aorta, arrhythmias and congenital heart disease, as well as in transversal research lines, as cardiac imaging (4D-Flow in cardiac NMR studies) or clinical epidemiology (cost-effectiveness, Composite-endpoints). Important advancements have been made in the transference of knowledge to the industry and the society, as the development of a new treatment against ischemia-reperfusion injury and adverse myocardial remodeling based on the inhibition of calpains.

VHIR Annual Report 2019

© FIR-HUVH Fundació Institut de Recerca Hospital Universitari Vall d’Hebron 2019 | Developed by: ondeuev